Current Strategies to Combat Cisplatin-Induced Ototoxicity
Cisplatin is widely used for the treatment of a number of solid malignant tumors. However, ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for this toxicity has not been fully elucidated. It is generally accepted that hearing loss is due to excessive produ...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00999/full |
id |
doaj-9b3b42358bde46f68027846622a8f8a5 |
---|---|
record_format |
Article |
spelling |
doaj-9b3b42358bde46f68027846622a8f8a52020-11-25T03:17:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-07-011110.3389/fphar.2020.00999553705Current Strategies to Combat Cisplatin-Induced OtotoxicityDehong Yu0Dehong Yu1Dehong Yu2Jiayi Gu3Jiayi Gu4Jiayi Gu5Yuming Chen6Yuming Chen7Yuming Chen8Wen Kang9Wen Kang10Wen Kang11Xueling Wang12Xueling Wang13Xueling Wang14Hao Wu15Hao Wu16Hao Wu17Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaEar Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300), Shanghai, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaEar Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300), Shanghai, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaEar Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300), Shanghai, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaEar Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300), Shanghai, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaEar Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300), Shanghai, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaEar Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300), Shanghai, ChinaCisplatin is widely used for the treatment of a number of solid malignant tumors. However, ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for this toxicity has not been fully elucidated. It is generally accepted that hearing loss is due to excessive production of reactive oxygen species by cells of the cochlea. In addition, recent data suggest that inflammation may trigger inner ear cell death through endoplasmic reticulum stress, autophagy, and necroptosis, which induce apoptosis. Strategies have been extensively explored by which to prevent, alleviate, and treat cisplatin-induced ototoxicity, which minimize interference with antitumor activity. Of these strategies, none have been approved by the Federal Drug Administration, although several preclinical studies have been promising. This review highlights recent strategies that reduce cisplatin-induced ototoxicity. The focus of this review is to identify candidate agents as novel molecular targets, drug administration routes, delivery systems, and dosage schedules. Animal models of cisplatin ototoxicity are described that have been used to evaluate drug efficacy and side effect prevention. Finally, clinical reports of otoprotection in patients treated with cisplatin are highlighted. For the future, high-quality studies are required to provide reliable data regarding the safety and effectiveness of pharmacological interventions that reduce cisplatin-induced ototoxicity.https://www.frontiersin.org/article/10.3389/fphar.2020.00999/fullcisplatin-induced ototoxicitydrug delivery systemsanimal modelsclinical trials |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dehong Yu Dehong Yu Dehong Yu Jiayi Gu Jiayi Gu Jiayi Gu Yuming Chen Yuming Chen Yuming Chen Wen Kang Wen Kang Wen Kang Xueling Wang Xueling Wang Xueling Wang Hao Wu Hao Wu Hao Wu |
spellingShingle |
Dehong Yu Dehong Yu Dehong Yu Jiayi Gu Jiayi Gu Jiayi Gu Yuming Chen Yuming Chen Yuming Chen Wen Kang Wen Kang Wen Kang Xueling Wang Xueling Wang Xueling Wang Hao Wu Hao Wu Hao Wu Current Strategies to Combat Cisplatin-Induced Ototoxicity Frontiers in Pharmacology cisplatin-induced ototoxicity drug delivery systems animal models clinical trials |
author_facet |
Dehong Yu Dehong Yu Dehong Yu Jiayi Gu Jiayi Gu Jiayi Gu Yuming Chen Yuming Chen Yuming Chen Wen Kang Wen Kang Wen Kang Xueling Wang Xueling Wang Xueling Wang Hao Wu Hao Wu Hao Wu |
author_sort |
Dehong Yu |
title |
Current Strategies to Combat Cisplatin-Induced Ototoxicity |
title_short |
Current Strategies to Combat Cisplatin-Induced Ototoxicity |
title_full |
Current Strategies to Combat Cisplatin-Induced Ototoxicity |
title_fullStr |
Current Strategies to Combat Cisplatin-Induced Ototoxicity |
title_full_unstemmed |
Current Strategies to Combat Cisplatin-Induced Ototoxicity |
title_sort |
current strategies to combat cisplatin-induced ototoxicity |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-07-01 |
description |
Cisplatin is widely used for the treatment of a number of solid malignant tumors. However, ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for this toxicity has not been fully elucidated. It is generally accepted that hearing loss is due to excessive production of reactive oxygen species by cells of the cochlea. In addition, recent data suggest that inflammation may trigger inner ear cell death through endoplasmic reticulum stress, autophagy, and necroptosis, which induce apoptosis. Strategies have been extensively explored by which to prevent, alleviate, and treat cisplatin-induced ototoxicity, which minimize interference with antitumor activity. Of these strategies, none have been approved by the Federal Drug Administration, although several preclinical studies have been promising. This review highlights recent strategies that reduce cisplatin-induced ototoxicity. The focus of this review is to identify candidate agents as novel molecular targets, drug administration routes, delivery systems, and dosage schedules. Animal models of cisplatin ototoxicity are described that have been used to evaluate drug efficacy and side effect prevention. Finally, clinical reports of otoprotection in patients treated with cisplatin are highlighted. For the future, high-quality studies are required to provide reliable data regarding the safety and effectiveness of pharmacological interventions that reduce cisplatin-induced ototoxicity. |
topic |
cisplatin-induced ototoxicity drug delivery systems animal models clinical trials |
url |
https://www.frontiersin.org/article/10.3389/fphar.2020.00999/full |
work_keys_str_mv |
AT dehongyu currentstrategiestocombatcisplatininducedototoxicity AT dehongyu currentstrategiestocombatcisplatininducedototoxicity AT dehongyu currentstrategiestocombatcisplatininducedototoxicity AT jiayigu currentstrategiestocombatcisplatininducedototoxicity AT jiayigu currentstrategiestocombatcisplatininducedototoxicity AT jiayigu currentstrategiestocombatcisplatininducedototoxicity AT yumingchen currentstrategiestocombatcisplatininducedototoxicity AT yumingchen currentstrategiestocombatcisplatininducedototoxicity AT yumingchen currentstrategiestocombatcisplatininducedototoxicity AT wenkang currentstrategiestocombatcisplatininducedototoxicity AT wenkang currentstrategiestocombatcisplatininducedototoxicity AT wenkang currentstrategiestocombatcisplatininducedototoxicity AT xuelingwang currentstrategiestocombatcisplatininducedototoxicity AT xuelingwang currentstrategiestocombatcisplatininducedototoxicity AT xuelingwang currentstrategiestocombatcisplatininducedototoxicity AT haowu currentstrategiestocombatcisplatininducedototoxicity AT haowu currentstrategiestocombatcisplatininducedototoxicity AT haowu currentstrategiestocombatcisplatininducedototoxicity |
_version_ |
1724631720541552640 |